BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Tuesday, August 6, 2024
Time: 8:30 AM Eastern Time
United States: 1-877-300-8521
International: 1-412-317-6026
Israel: 1-80-921-2373
Conference ID: 10190847
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2
   

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com

Staff

Recent Posts

Teaching Doctors in the World’s Fastest-Growing Economy – Texila American University in Guyana

GEORGETOWN, Guyana, March 31, 2025 /PRNewswire/ -- As Guyana rockets to the top of the…

5 hours ago

Healthcare Sector Faces Escalating Cybersecurity Risks Amid Digital Transformation

Advanced Security Solutions and Regulatory Compliance Key to Strengthening Resilience LONDON, March 31, 2025 /PRNewswire/…

5 hours ago

Living with a Bleeding Disorder

MISSION, Kan., March 31, 2025 /PRNewswire/ -- (Family Features) Many people don't think much about…

5 hours ago

Aetion Launches Aetion® Evidence Platform Availability in AWS Marketplace, Accelerating Real-World Evidence Benefits for its Customers

Aetion's industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering organizations to unlock…

5 hours ago

Eargo and hearX Close Merger, Announce New Combined Company, LXE Hearing

Two national hearing health brands combine to make high-quality hearing aids more accessible and affordable…

5 hours ago

Center for Transformative Dentistry Uses New Evidence-Based Treatment for TMJ

New Wholistic Solution Uses Imaging and Multidisciplinary Techniques to Address Root Causes of Jaw Disorders…

5 hours ago